Group 1 - Quantum-Si (NASDAQ: QSI) aims to introduce a scalable and cost-effective protein sequencing system, presenting a significant opportunity despite the challenges in protein sequencing [1] - Richard Durant leads Narweena, an asset manager focused on identifying market dislocations due to misunderstandings of long-term business prospects, targeting businesses with secular growth opportunities in markets with entry barriers [1] - Narweena's investment strategy emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and a long-term investment horizon, particularly favoring deeply undervalued small-cap stocks [1] Group 2 - The aging population, low population growth, and stagnating productivity growth are expected to create a different set of investment opportunities compared to the past, with some industries facing stagnation or secular decline [1] - A trend towards asset-light businesses is emerging, leading to a declining need for infrastructure investments, which is resulting in a large pool of capital chasing limited investment opportunities, driving up asset prices and compressing risk premia [1] - Richard Durant holds undergraduate degrees in engineering and finance and an MBA, and has passed the CFA exams, indicating a strong educational background in finance and investment [1]

Melbourne, Victoria, Australia--(Newsfile Corp. - March 10, 2025) - Besra Gold Inc (ASX: BEZ) ("Besra" or the "Company") announces that Quantum requests a special meeting of the shareholders.In accordance with ASX Listing Rule 3.17A, the Board of Besra Gold Inc (Corporation) advises that it has received a requisition for a special meeting of the shareholders of the Corporation (Requisition) under Section 143 of the Canada Business Corporations Act (Act). The Requisition states, "Under Section 143 of the Ac ...

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Quantum Computing Inc. (NASDAQ: QUBT).Shareholders who purchased shares of QUBT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/quantum-computing-inc-loss-submission-form/?id=134614&from=4CLASS PERIOD: March 3 ...

Core Viewpoint - Investors are shifting their focus from established AI giants to emerging opportunities in quantum computing, with IonQ being highlighted as a potential leader in this space [1][2]. Group 1: Quantum Computing Landscape - Quantum computing is gaining attention as a new megatrend, with the potential to solve complex problems much faster than classical supercomputers [5]. - IonQ has seen a significant increase in its stock price, rising by 222% over the last six months, positioning itself as a key player in the quantum computing sector [3]. Group 2: Comparison with Nvidia - IonQ's CEO has drawn parallels between IonQ's current position and Nvidia's status prior to the AI revolution, suggesting that IonQ could experience similar growth [6]. - In 2015, Nvidia generated $4.7 billion in revenue with a market capitalization of approximately $11.3 billion, while IonQ is currently much smaller and facing a higher cash burn rate [7][8]. Group 3: Valuation Concerns - IonQ's stock trades at a price-to-sales (P/S) ratio exceeding 100, in stark contrast to Nvidia's P/S ratio of 2.4 in early 2015, indicating a significant premium on IonQ's valuation [9][10]. - Despite the potential of quantum computing, IonQ's rapid valuation increase raises concerns about its sustainability, especially given its low sales traction and high cash burn rate [11].

Corporate Updates - Quantum BioPharma Ltd. has announced the cancellation of 7,692 warrants previously granted to Michael (Zappy) Zapolin, as they no longer served as a realistic incentive [2][3] - The company has granted 7,692 stock options to Mr. Zapolin with an exercise price of C$6.60 per Class B Share, expiring on March 7, 2027 [4] - The option grant is classified as a related party transaction, requiring minority shareholder approval and a formal valuation, but the Board determined it was exempt from these requirements [5] Financial Activities - On March 6, 2025, the company closed a fourth tranche of a previously announced offering, issuing 100 Debenture Units for $100,000, which will be used for business development and working capital [6] - The company may close additional tranches with an increased conversion price of $6.60 and an increased exercise price per Warrant Share of $7.00 [6] Company Overview - Quantum BioPharma focuses on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation [8][9] - The company retains a 25.71% ownership in Celly Nutrition Corp., which includes royalty payments of 7% of sales from its product unbuzzd™ until total payments reach $250 million, after which the royalty will drop to 3% [9]

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Quantum Computing Inc. ("Quantum Computing Inc." or the "Company") (NASDAQ: QUBT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Quantum Computing Inc. investors who were adversely affected by alleged securities fraud between March 30, 2020 and January 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Quantum Computing Inc. ("Quantum Computing Inc." or the "Company") (NASDAQ: QUBT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Quantum Computing Inc. investors who were adversely affected by alleged securities fraud between March 30, 2020 and January 15, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra ...

Rigetti Earnings Reveal the Risks and Rewards of Quantum Computing ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Quantum Computing Inc. (NASDAQ: QUBT).Shareholders who purchased shares of QUBT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/quantum-computing-inc-loss-submission-form/?id=134063&from=4 CLASS PERIOD: March 3 ...

Industry Overview - The artificial intelligence (AI) industry has rapidly risen, and quantum computing is poised to be the next hot sector, with the potential to transform industries even more than AI [1] - Quantum machines utilize subatomic particles for calculations at unprecedented speeds, enabling breakthroughs in various fields such as medicine, energy, and manufacturing [1] Company Analysis: Rigetti Computing - Rigetti Computing's shares have surged over 300% in the past 12 months due to investor optimism regarding quantum computing [3] - The company employs superconducting qubits and solid-state fabrication, aligning with existing semiconductor industry standards to facilitate customer adoption [4] - Despite the potential, Rigetti faces challenges with calculation errors in subatomic particles, limiting scalability and preventing replacement of current computers [5] - In Q3, Rigetti reported revenue of $2.4 million, a 23% decline from $3.1 million in 2023, marking the second consecutive quarter of year-over-year sales declines [6] - The cost of revenue increased by 41% year over year to $1.2 million, leading to a nearly 50% drop in Q3 gross profit to $1.2 million, and a net loss of $14.8 million [7] Company Analysis: IonQ - IonQ is developing networking technology to scale quantum machines, similar to conventional computing methods used in AI, resulting in a stock surge of over 140% in the past year [8] - IonQ's 2024 revenue reached $43.1 million, a 95% year-over-year increase, continuing a trend from 2023's $22 million, which was a 98% increase from 2022 [9] - The company announced advancements allowing its ion-based technology to produce vacuums comparable to those on the moon, enabling operation at room temperature and easing adoption [10] - IonQ's customer base includes notable companies such as AstraZeneca, Airbus, and the U.S. Air Force Research Lab [10] - Despite revenue growth, IonQ reported a net loss of $331.6 million in 2024, more than double the $157.8 million loss in 2023 [11] - Rising costs prompted IonQ to raise capital through an equity offering, which negatively impacted its stock due to shareholder dilution [12] Investment Comparison - Between Rigetti and IonQ, IonQ appears to be the superior investment due to its rapidly rising revenue compared to Rigetti's declining sales [13] - Both companies have high price-to-sales (P/S) ratios, indicating that investors are willing to pay a premium for their revenue [14] - The P/S multiples for both stocks have surged recently, suggesting a potential wait for lower prices before making investment decisions [15]